TargED enters clinic with Phase 1 trial of its groundbreaking thrombolytic TGD001

TargED is pleased to announce it has dosed the first participant with its groundbreaking thrombolytic drug, TGD001. This Phase 1a clinical trial will assess TGD001’s safety and tolerability in healthy volunteers.

TGD001 is a first-in-class ‘fusion protein’ drug with a unique two-step mode of action, which offers patients with clotting disorders the potential of a faster, safer and more effective treatment than currently available treatments.

Kristof Vercruysse, CEO and co-founder of TargED, commented: “Blood clotting disorders account for around 16 million deaths per year worldwide, almost half of that number from acute ischemic stroke (AIS) alone. But currently available thrombolytics, which break down blood clots, have significant drawbacks which limit their safety, effectiveness and applicability. Because TGD001’s unique mode of action means it does not suffer from the problems of today’s thrombolytics, we believe it will be a safer, more effective and more widely usable treatment – for a wide range of thrombotic disorders. The start of this Phase 1 clinical trial is an important milestone on our journey to reach that objective.”

The first safety read-out is expected by mid-2025. TargED then plans to start two proof-of-concept trials in the second half of 2025: a Phase 2a in patients with acute ischaemic stroke (AIS) and a Phase 1b trial in patients with the rare micro-clotting disorder immune-mediated thrombotic thrombocytopenic purpura (iTTP).